GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (NAS:BNGOW) » Definitions » Total Liabilities

Bionano Genomics (Bionano Genomics) Total Liabilities : $75.22 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Bionano Genomics Total Liabilities?

Bionano Genomics's Total Liabilities for the quarter that ended in Mar. 2024 was $75.22 Mil.

Bionano Genomics's quarterly Total Liabilities increased from Sep. 2023 ($62.91 Mil) to Dec. 2023 ($118.25 Mil) but then declined from Dec. 2023 ($118.25 Mil) to Mar. 2024 ($75.22 Mil).

Bionano Genomics's annual Total Liabilities increased from Dec. 2021 ($39.98 Mil) to Dec. 2022 ($58.10 Mil) and increased from Dec. 2022 ($58.10 Mil) to Dec. 2023 ($118.25 Mil).


Bionano Genomics Total Liabilities Historical Data

The historical data trend for Bionano Genomics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics Total Liabilities Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 26.59 25.37 39.98 58.10 118.25

Bionano Genomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.66 56.63 62.91 118.25 75.22

Bionano Genomics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bionano Genomics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=100.028+(7.175+10.89
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.154+0)
=118.25

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=214.404-96.157
=118.25

Bionano Genomics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=58.506+(6.33+10.25
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.138+0)
=75.22

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=157.995-82.771
=75.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bionano Genomics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionano Genomics (Bionano Genomics) Business Description

Traded in Other Exchanges
Address
9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas.